Cure My Disease

Don't miss your cure!

 Log in / Sign up

Texts and EHR nudges aim to close the breast cancer screening gap

NCT ID NCT06177795

Prevention Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether simple nudges—like text message reminders for patients and automatic mammogram orders for doctors—can increase breast cancer screening among women aged 40 to 74 who are overdue for a mammogram. The trial involves over 21,000 women at two health systems. Some participants receive text reminders to schedule their mammogram, while their doctors get a pre-filled order in the electronic health record. The goal is to see if these gentle pushes help more women complete screening within three to six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
text message reminders and electronic health record prompts
What this could lead to
If successful, this approach could provide a simple, scalable way to boost breast cancer screening rates, catching cancers earlier and saving lives.
What could go wrong
The trial tests behavioral nudges, not a new medical treatment, so the impact may be modest. Results depend on how well patients and clinicians respond to reminders, and may not apply to all healthcare settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

21,123 people

The number who actually took part.

Started

Dec 2023

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 74 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All patients must meet the following criteria to be eligible: 1. Women between 40 and 74 years of age 2. A scheduled new or return (non-urgent/sick) primary care visit at one of the study practices (Penn Trial) or with one of the study primary care providers (UH Trial) 3. Are overdue and eligible for a mammogram per Health Maintenance 4. Does not have a future scheduled mammogram appointment For the Penn Trial patient intensification nudge, at least one of the following criteria must be met to be considered high risk and randomized to receive the intensification nudge: 1. Medicare Insurance 2. Medicaid Insurance 3. No EHR patient portal account 4. Zero log-ins to EHR patient portal in the previous year Exclusion Criteria: Patients will be excluded from the study if: 1. History of bilateral mastectomy 2. Have a mammogram exclusion modifier in Health Maintenance 3. Have no phone number (home or mobile) listed in their chart (Penn Trial only)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Case Western Reserve University/University Hospitals

    Cleveland, Ohio, 44106, United States

  • University of Pennsylvania Health System

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.